Gavi launches Advance Market Commitment to accelerate production of pneumococcal vaccines targeting needs of developing countries
Pneumococcal disease is one of the biggest vaccine preventable killers of children today, but now, thanks to the Advance Market Commitment (AMC), that's all about to change.
To accelerate the development and production of a new generation of pneumococcal vaccines - better targeted to the epidemiology in developing countries and made more affordable - Gavi, the World Bank and donors launched the pneumococcal Advance Market Commitment (AMC) in 2009.
Thanks to agreements between Gavi and two manufacturers to date, the Vaccine Alliance and developing countries will pay a maximum US$3.50 per dose of pneumococcal vaccines procured in the coming years - less than 10% of the cost of the same vaccines currently being sold in the European Union and United States.1
Gavi expects additional manufacturers from emerging markets to submit new pneumococcal vaccines for participation in the AMC in the near future.
The AMC was designed to give manufacturers an incentive to invest in:
- finalising pneumococcal vaccines that include coverage for the additional serotypes which commonly cause disease and death in low-income countries;
- increasing manufacturing capacity to provide the appropriate pneumococcal vaccines in sufficient quantities to meet demand.
At the same time, developing country governments can budget and plan for their immunisation programmes, knowing that vaccines will be available in sufficient quantity and at a price they can afford in the long-term.
Parallel to the AMC and to help developing countries lay the groundwork for introducing pneumococcal vaccines as soon as they become available, Gavi set-up the Pneumococcal vaccine Accelerated Development and Introduction Plan (PneumoADIP) in 2003.
The Vaccine Alliance and the Pneumococcal AMC
- The World Bank: fiduciary support.
- Industrialised countries: the governments of Italy, the United Kingdom, Canada, Russia, Norway and the Bill & Melinda Gates Foundation committed a total US$1.5 bilion to launch the programme.
- Gavi committed to US$ 1.3 billion to support the cost of vaccines from 2010-2015, as well as programmatic and administrative support.
- WHO established the minimum technical criteria for the vaccines and provides technical assistance as required.
- UNICEF is responsible for vaccine procurement and distribution.
Based at the John Hopkins Bloomberg School of Public Health in Baltimore, USA, the PneumoADIP worked to increase demand for and access to pneumococcal vaccines by establishing and communicating the evidence base around burden and epidemiology of pneumococcal disease for decision-making in low-income countries, supporting the development of financing mechanisms and ensuring adequate supply to meet demand. More information about the PneumoADIP may be obtained by contacting the International Vaccine Access Center at Johns Hopkins University.
Routine immunisation support
In the same year, following an investment case developed by the PneumoADIP, Gavi decided to offer financial support for the introduction of pneumococcal vaccines through its new and underused vaccine programme.
From 2010-2015, Gavi has endorsed up to US$ 1.3 billion to fund pneumococcal vaccines that are suitable for low-income countries through the AMC.
To be AMC eligible, vaccines must meet specific criteria developed by WHO and be approved by the Independent Assessment Committee (IAC) of the AMC.